首页> 外文期刊>Clinical Psychopharmacology and Neuroscience >Occupancy of α7 Nicotinic Acetylcholine Receptors in the Brain by Tropisetron: A Positron Emission Tomography Study Using [11C]CHIBA-1001 in Healthy Human Subjects
【24h】

Occupancy of α7 Nicotinic Acetylcholine Receptors in the Brain by Tropisetron: A Positron Emission Tomography Study Using [11C]CHIBA-1001 in Healthy Human Subjects

机译:Tropisetron在大脑中占有α7烟碱乙酰胆碱受体的作用:使用[11C] CHIBA-1001在健康人体中进行的正电子发射断层扫描研究

获取原文
       

摘要

Objective Agonists of α7-nicotinic acetylcholine receptors (nAChRs) have been developed as potential therapeutic drugs for neuropsychiatric diseases such as schizophrenia and Alzheimer's disease. Positron emission tomography (PET) is a noninvasive brain imaging technique to measure receptor occupancy in the living human brain. Although much effort has been expended to create specific PET radioligands for α7-nAChRs in the brain, only 4-[11C]methylphenyl-1,4-diazabicyclo[3.2.2.]nonane-4-carboxylate ([11C]CHIBA-1001) is currently available for clinical studies. In contrast, two 5-hydroxytryptamine-3 (5-HT3) receptor antagonists, tropisetron and ondansetron, have been used to treat patients with chemotherapy-induced or postoperative nausea and vomiting. Furthermore, tropisetron, but not ondansetron, possesses high affinity for α7-nAChRs. In the present study, we evaluated the receptor occupancy in the human brain after a single oral administration of tropisetron and ondansetron using [11C]CHIBA-1001 and PET. Methods Two serial dynamic PET scans using [11C]CHIBA-1001 in healthy non-smoking male subjects were performed before and after receiving an oral administration of these medications. Results A single oral administration of tropisetron, but not ondansetron, decreased the total distribution volume of [11C]CHIBA-1001 in the human brain. Conclusion This study shows that tropisetron, but not ondansetron, could bind to α7-nAChRs in the human brain after a single oral administration. Therefore, [11C]CHIBA-1001 may be a useful PET radioligand to measure the occupancy of α7-nAChRs in the human brain.
机译:目的已开发出α7烟碱型乙酰胆碱受体(nAChRs)激动剂作为神经精神疾病如精神分裂症和阿尔茨海默氏病的潜在治疗药物。正电子发射断层扫描(PET)是一种非侵入性的大脑成像技术,可以测量人的活脑中的受体占有率。尽管已花费大量努力来为大脑中的α7-nAChRs创建特定的PET放射性配体,但只有4-[ 11 C]甲基苯基-1,4-二氮杂双环[3.2.2。]壬烷-4-羧酸盐([ 11 C] CHIBA-1001)目前可用于临床研究。相比之下,两种5-羟色胺-3(5-HT 3 )受体拮抗剂托非司琼和恩丹西酮已被用于治疗化疗引起的或术后恶心和呕吐的患者。此外,托吡司琼而不是昂丹西酮对α7-nAChR具有高亲和力。在本研究中,我们评估了使用[ 11 C] CHIBA-1001和PET单次口服托吡司琼和恩丹西酮后在人脑中的受体占有率。方法在健康非吸烟男性受试者中,在口服这些药物之前和之后,使用[ 11 C] CHIBA-1001进行了两次连续动态PET扫描。结果单次口服托吡司琼而不是恩丹西酮减少了[ 11 C] CHIBA-1001在人脑中的总分布量。结论这项研究表明,单次口服后,托吡司琼可与人脑中的α7-nAChRs结合,而不与恩丹西酮结合。因此,[ 11 C] CHIBA-1001可能是一种有用的PET放射性配体,可用于测量人脑中α7-nAChRs的占有率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号